Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2300-2308

  Murray, Nevin ^a   Livingston, Robert B ^a   Shepherd, Frances A ^a   James, Keith ^a   Zee, Benny ^a   Langleben, A ^a   Kraut, Michael ^a   Bearden, James ^a   Wendall Goodwin, J ^a   Grafton, Clive ^a   Turrisi, Andrew ^a   Walde, David ^a   Croft, Herbert ^a   Osoba, David ^a   Ottaway, Jon ^a   Gandara, David ^a  

^a Queen's Cancer Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0032793437     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2300     Document Type: Article

References (26)

1. Ihde DH: Chemotherapy for lung cancer. N Engl J Med 327:1434-1441, 1992
2. Figueredo AT, Hryniuk WM, Strautmanis I, et al: Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 3:54-64, 1985
3. Johnson DH, Einhorn LH, Birch R, et al: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731-1738, 1987
4. Ihde DH, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022-2034, 1994
5. Cohen MH, Creaven PJ, Fossieck BE, et al: Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61:348-354, 1977
6. Murray N: Importance of dose and dose intensity in the treatment of small-cell lung cancer. Cancer Chemother Pharmacol 40:S58-S63, 1997 (suppl)
7. Murray N, Shah A, Osoba D, et al: Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9:1632-1638, 1991
8. Hande KR, Bennett RB, Krozley MG: Improved bioavailability with low dose oral etoposide. J Clin Oncol 11:374-7, 1993
9. Murray N: Weekly chemotherapy for small cell lung cancer. Lung Cancer 11:138-139, 1994 (suppl 2)
10. Livingston RB, Schulman S, Mira JG, et al: Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: A Southwest Oncology Group study. Cancer Treat Rep 70:1395-1401, 1986
11. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107:451-458, 1987
12. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 282-291, 1992
13. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
14. Coppin C: The description of chemotherapy delivery: Options and pitfalls. Semin Oncol 14:34-42, 1987 (suppl 4)
15. Zee B: Growth curve model analysis for quality of life data. Stat Med 17:757-766, 1998
16. Withers HR: Biological basis of radiation therapy for cancer. Lancet 339:156-163, 1992
17. Sculier JP, Paesmans M, Bureau G, et al: Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: A phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 11:1858-1865, 1993
18. Souhami RL, Rudd R, Ruiz de Elvira MC, et al: Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: A Cancer Research Campaign Trial. J Clin Oncol 12:1806-1813, 1994
19. Kubota K, Nishiwaki Y, Kakinuma R, et al: Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 15:292-296, 1997
20. Aisner J, Alberto P, Bitran J, et al: Role of chemotherapy in small cell lung cancer: A consensus report of the International Association for the Study of Lung Cancer Workshop. Cancer Treat Rep 67:37-43, 1983
21. Fukuoka M, Masuda N, Negoro S, et al: CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 75:306-309, 1997
22. Furuse K, Kubota K, Nishiwaki Y, et al: Phase III study of dose intensive weekly chemotherapy with recombinant human granulocytecolony stimulating factor versus standard chemotherapy in extensive disease small cell lung cancer. J Clin Oncol 16:2126-2132, 1998
23. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): Report of a Southwest Oncology Group Study (SWOG-9308). J Clin Oncol 16:2459-2465, 1998
24. Bonomi P, Kim K, Chang A, et al: Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF(G) versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 15:382, 1996 (abstr 1145)
25. Arriagada R, Le Chevalier T, Pignon JP, et al: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329:1848-1852, 1993
26. Mehta C, Vogl SE: High-dose cyclophosphamide in the induction therapy of small cell lung cancer: Minor improvements in rate of remission and survival. Proc Am Assoc Cancer Res 23:155, 1982 (abstr 612)